Align Technology, Inc.
ALGN · NASDAQ Global Select · USD
174,26USD
0,00 (0,00 %)Stand 10. Nov., 21:00
Nachbörslich176,10+1,84 (+1,05 %)19:37 ET
Kennzahlen
- Eröffnung
- 171,82
- Vortag
- 174,26
- Tagesspanne
- 171,00 – 175,81
- 52 Wochen
- 130,23 – 200,44
- Volumen
- 1,91 Mio.
- Ø Volumen
- 967.389
- Börsenwert
- 12,38 Mrd. $
- KGV
- 25,3
- Gewinn je Aktie (TTM)
- 6,88
- Dividendenrendite
- 0,0 %
- Beta
- 1,7
- Nächste Zahlen
- 3. Feb. 2027
Finanzen
| USD | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Umsatz | 4,03 Mrd. | 4 Mrd. | 3,86 Mrd. | 3,73 Mrd. | 3,95 Mrd. |
| Herstellungskosten | 1,28 Mrd. | 1,2 Mrd. | 1,16 Mrd. | 1,1 Mrd. | 1,02 Mrd. |
| Bruttogewinn | 2,76 Mrd. | 2,8 Mrd. | 2,71 Mrd. | 2,63 Mrd. | 2,94 Mrd. |
| Forschung und Entwicklung | 369,91 Mio. | 364,2 Mio. | 346,83 Mio. | 305,26 Mio. | 250,32 Mio. |
| Vertrieb und Verwaltung | 1,76 Mrd. | 1,76 Mrd. | 1,7 Mrd. | 1,67 Mrd. | 1,71 Mrd. |
| Operatives Ergebnis | 616,22 Mio. | 607,63 Mio. | 643,34 Mio. | 642,6 Mio. | 976,4 Mio. |
| EBITDA | 822,72 Mio. | 816,8 Mio. | 799,06 Mio. | 779,84 Mio. | 1,12 Mrd. |
| Nettogewinn | 410,35 Mio. | 421,36 Mio. | 445,05 Mio. | 361,57 Mio. | 772,02 Mio. |
| Gewinn je Aktie (verwässert) | 5,65 | 5,62 | 5,81 | 4,61 | 9,69 |
Umsatz nach Segment
Produkte · FY 2025
- Clear Aligner3,25 Mrd. $80,43 %+0,47 %
- Scanners And Services789,56 Mio. $19,57 %+2,69 %
Anteil · ggü. Vorjahr (FY 2024)
Regionen · FY 2025
- UNITED STATES1,66 Mrd. $41,17 %−2,04 %
- Other International1,45 Mrd. $36,01 %+10,12 %
- SWITZERLAND920,59 Mio. $22,82 %−6,41 %
Anteil · ggü. Vorjahr (FY 2024)
Bewertung
Letzte 12 Monate
- KGV
- 25,3
- Kurs-Umsatz-Verhältnis
- 3,0
- Kurs-Buchwert-Verhältnis
- 2,9
- PEG
- 0,8
- Bruttomarge
- 67,6 %
- Operative Marge
- 15,0 %
- Nettomarge
- 11,8 %
- Verschuldungsgrad
- 0,0
- EV/EBITDA
- 15,3
- Eigenkapitalrendite
- 11,8 %
- Kapitalrendite (ROIC)
- 10,3 %
- Free-Cashflow-Rendite
- 4,9 %
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | |
|---|---|---|---|---|---|
| Bruttomarge | 68,3 % | 70,0 % | 70,1 % | 70,5 % | 74,3 % |
| Operative Marge | 15,3 % | 15,2 % | 16,7 % | 17,2 % | 24,7 % |
| Nettomarge | 10,2 % | 10,5 % | 11,5 % | 9,7 % | 19,5 % |
| KGV | 27,6 | 37,0 | 47,1 | 45,6 | 67,2 |
| Kurs-Umsatz-Verhältnis | 2,8 | 3,9 | 5,4 | 4,4 | 13,1 |
| Kurs-Buchwert-Verhältnis | 2,8 | 4,1 | 5,8 | 4,6 | 14,3 |
| Verschuldungsgrad | 0,0 | 0,0 | 0,0 | 0,0 | 0,0 |
| Liquidität 3. Grades | 1,4 | 1,2 | 1,2 | 1,3 | 1,3 |
| Dividendenrendite | 0,0 % | 0,0 % | 0,0 % | 0,0 % | 0,0 % |
| Unternehmenswert | 10,36 Mrd. | 14,69 Mrd. | 20,13 Mrd. | 15,68 Mrd. | 50,89 Mrd. |
| EV/EBITDA | 12,6 | 18,0 | 25,2 | 20,1 | 45,4 |
| Eigenkapitalrendite | 10,1 % | 10,9 % | 12,3 % | 10,0 % | 21,3 % |
| Kapitalrendite (ROIC) | 9,9 % | 10,0 % | 11,0 % | 9,6 % | 18,4 % |
| Free-Cashflow-Rendite | 4,3 % | 4,0 % | 2,9 % | 1,7 % | 1,5 % |
Wachstum
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | |
|---|---|---|---|---|---|
| Umsatz | +0,9 % | +3,5 % | +3,4 % | −5,5 % | +59,9 % |
| Bruttogewinn | −1,5 % | +3,4 % | +2,8 % | −10,3 % | +66,5 % |
| Operatives Ergebnis | +1,4 % | −5,6 % | +0,1 % | −34,2 % | +152,2 % |
| Nettogewinn | −2,6 % | −5,3 % | +23,1 % | −53,2 % | −56,5 % |
| Gewinn je Aktie | +0,5 % | −3,3 % | +26,0 % | −52,4 % | −56,8 % |
| Freier Cashflow | −21,2 % | +2,4 % | +119,6 % | −64,1 % | +52,1 % |
| Dividende je Aktie | 0,0 % | 0,0 % | 0,0 % | 0,0 % | 0,0 % |
Analysten
Einstufungen · Buy
- 0Stark kaufen
- 22Kaufen
- 9Halten
- 2Verkaufen
- 0Stark verkaufen
Kursziel
190,00
Durchschnitt · +9,03 %
Schätzungen
| FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|
| Umsatz (Ø) | 4,13 Mrd. | 4,25 Mrd. | 4,41 Mrd. |
| Umsatz (Tief – Hoch) | 4,12 Mrd. – 4,2 Mrd. | 4,12 Mrd. – 4,33 Mrd. | 4,22 Mrd. – 4,59 Mrd. |
| Gewinn je Aktie (Ø) | 11,14 | 12,30 | 13,41 |
| Gewinn je Aktie (Tief – Hoch) | 11,02 – 11,32 | 11,95 – 12,75 | 11,94 – 14,77 |
| Analysten | 9 | 10 | 6 |
Letzte Änderungen
- Morgan Stanley29. Okt. 2026Equal Weight
- Mizuho22. Okt. 2026Outperform
- Piper Sandler21. Okt. 2026Overweight
- Baird15. Okt. 2026Outperform → Neutral
- Leerink Partners14. Okt. 2026Outperform
- Stifel9. Okt. 2026Buy
- Evercore ISI Group5. Okt. 2026Outperform → In Line
- UBS23. Juli 2026Neutral
Quartalszahlen
Nächste Zahlen: 3. Feb. 2027| Okt. 2026 | Juli 2026 | Apr. 2026 | Feb. 2026 | Okt. 2025 | Juli 2025 | Apr. 2025 | Feb. 2025 | |
|---|---|---|---|---|---|---|---|---|
| Gewinn je Aktie · Erwartet | 2,77 | 2,62 | 2,30 | 2,99 | 2,40 | 2,57 | 1,99 | 2,43 |
| Gewinn je Aktie · Tatsächlich | 2,80 | 2,64 | 2,58 | 3,29 | 2,61 | 2,49 | 2,13 | 2,44 |
| Abweichung | +1,08 % | +0,76 % | +12,17 % | +10,03 % | +8,75 % | −3,11 % | +7,04 % | +0,41 % |
| Umsatz · Tatsächlich | 1,01 Mrd. | 1,06 Mrd. | 1,04 Mrd. | 1,05 Mrd. | 995,69 Mio. | 1,01 Mrd. | 979,26 Mio. | 995,22 Mio. |
Dividenden und Splits
Keine Dividenden gezahlt.
Aktiensplits
–
Eigentümer
Institutionen
Q2 2026 · 13F
- Anteil institutioneller Investoren
- 102,77 %
- Investoren mit 13F-Meldung
- 712
Größte Investoren
- BLACKROCK, INC.6,18 %4,42 Mio.
- VANGUARD CAPITAL MANAGEMENT LLC6,16 %4,4 Mio.
- FMR LLC5,68 %4,06 Mio.
- CAPITAL INTERNATIONAL INVESTORS5,66 %4,05 Mio.
- CAPITAL WORLD INVESTORS4,79 %3,42 Mio.
- GOLDMAN SACHS GROUP INC4,72 %3,37 Mio.
- VANGUARD PORTFOLIO MANAGEMENT LLC4,38 %3,13 Mio.
- STATE STREET CORP3,58 %2,56 Mio.
Insider-Geschäfte
- Davis Jennifer L.2. Nov. 2026 · director, officer: CEO-electVerkauf0 Aktien
- Blackford Quentin S.27. Aug. 2026 · directorKauf1376 Aktien
- Blackford Quentin S.27. Aug. 2026 · Verkauf0 Aktien
- Vitalone Britt J.20. Mai 2026 · directorKauf1836 Aktien
- Vitalone Britt J.20. Mai 2026 · directorKauf1443 Aktien
- Vitalone Britt J.20. Mai 2026 · directorVerkauf1443 Aktien
- SIEGEL SUSAN E20. Mai 2026 · directorKauf1745 Aktien
- SIEGEL SUSAN E20. Mai 2026 · directorKauf1836 Aktien
Vergleichbare Unternehmen
Über das Unternehmen
Align Technology, Inc. is a medical technology enterprise that develops, produces, and markets its leading products: Invisalign transparent dental aligners and iTero digital intraoral scanners, along with related services. These offerings serve a wide range of dental professionals, including orthodontists, general dentists, and those specializing in restorative and cosmetic dentistry. The company's operations are divided into two main business units: "Clear Aligner" and "Scanners and Services." The Clear Aligner segment offers a variety of solutions. Its comprehensive products include the full Invisalign treatment for teenage patients, designed to address complex orthodontic needs such as mandibular advancement, patient compliance tracking, and managing tooth eruption. It also features specialized Invisalign First Phase I and Phase 2 packages for younger children, typically aged seven to ten, who have mixed dentition (a combination of primary and permanent teeth). Beyond these, the segment provides non-comprehensive aligner options like Invisalign moderate, lite, express, and Invisalign Go. Additional non-case products include retention devices, fees for Invisalign training, and sales of ancillary items such as cleaning materials and adjustment tools used by dental practitioners during treatment. The Scanners and Services segment centers around the iTero scanner, a unified hardware platform offering various software applications for both restorative and orthodontic procedures. It supplies specialized restorative software to general dentists, prosthodontists, periodontists, and oral surgeons, as well as distinct software for orthodontists to manage digital patient records, perform diagnoses, and facilitate the fabrication of printed models and retainers. This segment also provides computer-aided design and manufacturing (CAD/CAM) services, along with supplementary products like disposable covers for the scanner wand and iTero models and dies. Furthermore, it includes third-party scanners and digital scan solutions, the Invisalign Outcome Simulator (a chair-side and cloud-based application for the iTero scanner), the Invisalign Progress Assessment tool, and TimeLapse technology, which enables clinicians to compare a patient's historical 3D scans against current data. Align Technology distributes its products worldwide, with a strong presence in the United States, Switzerland, and China. Founded in 1997, the company is headquartered in Tempe, Arizona.
Führung
- Joseph HoganPresident, Chief Executive Officer & Director
- Zelko RelicExecutive Vice President & Chief Technology Officer
- John F. MoriciChief Financial Officer & Executive Vice President of Global Finance
- Richardson Jaime HolteExecutive Vice President of Global Human Resources
- Sreelakshmi KolliExecutive Vice President & Chief Product and Digital Officer
- Mitra DerakhshanExecutive VP, Chief Clinical Officer, Global Treatment Planning & Clinical Services
- CEO
- Joseph Hogan
- Mitarbeitende
- 20.290
- Hauptsitz
- Tempe, AZ, US
- Sektor
- Healthcare
- Branche
- Medical - Devices
- Börsengang
- 30. Jan. 2001
- Website
- aligntech.com
Nachrichten
- Business Wire · 10. Nov., 16:00Align Technology to Speak at Upcoming Financial Conference
- Business Wire · 6. Nov., 12:59Align Technology Recognized in Extel's 2026 All-America Executive Team Rankings
- Business Wire · 6. Nov., 9:10Align Technology Announces $270 Million Accelerated Stock Repurchase Agreement
- Seeking Alpha · 2. Nov., 16:36Align Technology: Q3 Results Expose Weak Pricing Power Amidst Declining Market Share
- Business Wire · 2. Nov., 16:00Align Technology Opens 2027 Annual Research Program to Advance Orthodontic and Dental Patient Care
- Seeking Alpha · 30. Okt., 14:11Align Technology: The Competitive Threat Has Eased, But Growth Remains A Concern
- Zacks Investment Research · 29. Okt., 13:11ALGN Q3 Earnings & Revenues Beat, '26 Sales View Down, Stock Falls
- MarketBeat · 28. Okt., 22:05Align Technology Q3 Earnings Call Highlights
- Seeking Alpha · 28. Okt., 22:00Align Technology, Inc. (ALGN) Q3 2026 Earnings Call Transcript
- Zacks Investment Research · 28. Okt., 18:31Compared to Estimates, Align Technology (ALGN) Q3 Earnings: A Look at Key Metrics
Kurse mindestens 15 Minuten verzögert. Daten: Financial Modeling Prep. Keine Anlageberatung.